Rahaman MH - Search Results

1

Targeting CDK9: a promising therapeutic opportunity in prostate cancer.

Rahaman MH, Kumarasiri M, Mekonnen LB, Yu M, Diab S, Albrecht H, Milne RW, Wang S. Rahaman MH, et al. Endocr Relat Cancer. 2016 Dec;23(12):T211-T226. doi: 10.1530/ERC-16-0299. Epub 2016 Aug 31. Endocr Relat Cancer. 2016. PMID: 27582311 Review.

2

Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.

Tadesse S, Yu M, Mekonnen LB, Lam F, Islam S, Tomusange K, Rahaman MH, Noll B, Basnet SK, Teo T, Albrecht H, Milne R, Wang S. Tadesse S, et al. Among authors: rahaman mh. J Med Chem. 2017 Mar 9;60(5):1892-1915. doi: 10.1021/acs.jmedchem.6b01670. Epub 2017 Feb 16. J Med Chem. 2017. PMID: 28156111 Free article.

3

Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia.

Diab S, Abdelaziz AM, Li P, Teo T, Basnet SKC, Noll B, Rahaman MH, Lu J, Hou J, Yu M, Le BT, Albrecht H, Milne RW, Wang S. Diab S, et al. Among authors: rahaman mh. Eur J Med Chem. 2017 Oct 20;139:762-772. doi: 10.1016/j.ejmech.2017.08.006. Epub 2017 Aug 3. Eur J Med Chem. 2017. PMID: 28863357

4

CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.

Rahaman MH, Yu Y, Zhong L, Adams J, Lam F, Li P, Noll B, Milne R, Peng J, Wang S. Rahaman MH, et al. Invest New Drugs. 2019 Aug;37(4):625-635. doi: 10.1007/s10637-018-0661-2. Epub 2018 Sep 8. Invest New Drugs. 2019. PMID: 30194564

5

Targeting CDK9 for treatment of colorectal cancer.

Rahaman MH, Lam F, Zhong L, Teo T, Adams J, Yu M, Milne RW, Pepper C, Lokman NA, Ricciardelli C, Oehler MK, Wang S. Rahaman MH, et al. Mol Oncol. 2019 Oct;13(10):2178-2193. doi: 10.1002/1878-0261.12559. Epub 2019 Aug 21. Mol Oncol. 2019. PMID: 31398271 Free PMC article.

6

CDK12: a potential therapeutic target in cancer.

Emadi F, Teo T, Rahaman MH, Wang S. Emadi F, et al. Among authors: rahaman mh. Drug Discov Today. 2020 Dec;25(12):2257-2267. doi: 10.1016/j.drudis.2020.09.035. Epub 2020 Oct 7. Drug Discov Today. 2020. PMID: 33038524 Review.

7

Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.

Yu M, Teo T, Yang Y, Li M, Long Y, Philip S, Noll B, Heinemann GK, Diab S, Eldi P, Mekonnen L, Anshabo AT, Rahaman MH, Milne R, Hayball JD, Wang S. Yu M, et al. Among authors: rahaman mh. Eur J Med Chem. 2021 Mar 15;214:113248. doi: 10.1016/j.ejmech.2021.113248. Epub 2021 Feb 3. Eur J Med Chem. 2021. PMID: 33571827

8

Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition.

Islam S, Rahaman MH, Yu M, Noll B, Martin JH, Wang S, Head R. Islam S, et al. Among authors: rahaman mh. Cancers (Basel). 2023 Feb 7;15(4):1044. doi: 10.3390/cancers15041044. Cancers (Basel). 2023. PMID: 36831387 Free PMC article.

9

Receptor model-based sources and risk assessment of metals in sediment of the coastal construction-oriented aquatic system in Bangladesh.

Rahman MH, Chen T, Yeasmin SM, Khan MHR, Chakraborty TK, Rahaman MH, Rahman MA. Rahman MH, et al. Among authors: rahaman mh. Mar Pollut Bull. 2024 May;202:116383. doi: 10.1016/j.marpolbul.2024.116383. Epub 2024 Apr 26. Mar Pollut Bull. 2024. PMID: 38677105

10

Molecular transformation of dissolved organic matter in manganese ore-mediated constructed wetlands for fresh leachate treatment.

Rahaman MH, Yang T, Zhang Z, Liu W, Chen Z, Mąkinia J, Zhai J. Rahaman MH, et al. J Environ Manage. 2024 May;358:120834. doi: 10.1016/j.jenvman.2024.120834. Epub 2024 Apr 16. J Environ Manage. 2024. PMID: 38631170

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

36 results

Search Page